Uppsala, Sweden – Cancerfonden, one of the largest contributors to cancer research projects in Sweden will fund a project aimed at an improved understanding of mechanisms behind Adaptable Drug Affinity Conjugate (ADAC™) technology and investigating the potential for using the technology in combination with other therapies.

The project was granted to Associate Professor Sara Mangsbo in her role as Senior Lecturer Antibody-based Drugs in the Department of Pharmacy at Uppsala University, Sweden (www.farmaci.uu.se).

Dr. Mangsbo, who is also Chief Scientific Officer at Strike Pharma, commented, “My research group is extremely pleased to receive this funding from such a well-respected and well-established organization. Improving the mechanistic understanding of ADAC technology can also aid and speed-up future translational initiatives which, ultimately, will be important for patients.

Mårten Winge, CEO of Strike Pharma added, “This funding is important for the long-term and expanded potential of ADAC technology, enabling Sara and her team to investigate the technology in depth. Today, our company is focused on the development of clinically-relevant candidates for use as immunotherapeutics for the treatment of solid tumors, using ADAC technology as the foundation for drug development. For the benefit of patients, academic research and industrial development must converge in order to support efforts in bringing effective and safe drugs to clinical testing and use.”


About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic treatment of solid tumors. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.


Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]